Javier Olazarán

Javier Olazarán

Auto-generated profile, based on publicly available information

Javier Olazarán

Alzheimer Disease Research Unit, Alzheimer Center Reina Sofía Foundation, CIEN Foundation, Carlos III Institute of Health, Madrid, Spain

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2015 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
MSMeritxell Valentí Soler
Meritxell Valentí Soler
LALuis Agüera-Ortiz
Luis Agüera-Ortiz
JRJavier Olazarán Rodríguez
Javier Olazarán Rodríguez
CRCarolina Mendoza Rebolledo
Carolina Mendoza Rebolledo
AMAlmudena Pérez Muñoz
Almudena Pérez Muñoz
PMPablo Martínez Martín
Pablo Martínez Martín
Aims: Testing the effect of the experimental robot-based therapeutic sessions for patients with dementia in: a controlled study of parallel groups of nursing home patients comparing the effects of therapy sessions utilizing a humanoid robot (NAO), an animal-shaped robot (PARO), or a trained dog (DOG), with conventional therapy (CONTROL) on symptoms of dementia; and an experience for patients who attend a day care center, comparing symptom prevalence and severity before and after sessions utilizing NAO and PARO. Methods: In the nursing home, patients were randomly assigned by blocks, based on dementia severity, to one of the 3 therapeutic groups to compare: CONTROL, PARO and NAO (phase 1) and CONTROL, PARO and DOG (phase 2). In the day care center, all patients received therapy with NAO (phase 1) and PARO (phase 2). Therapy sessions were held 2 days/week for 3 months. Evaluation at baseline and follow-up was carried out by blind raters using: the Global Deterioration Scale (GDS), the Severe Mini Mental State Examination (sMMSE), the Mini Mental State Examination (MMSE), the Neuropsychiatric Inventory (NPI), the Apathy Scale for Institutionalized Patients with Dementia Nursing Home version (APADEM-NH), the Apathy Inventory (AI) and the Quality of Life Scale (QUALID). Statistical analysis included descriptive statistics and non parametric tests performed by a blinded investigator. Results: In the nursing home, 101 patients (phase 1) and 110 patients (phase 2) were included. There were no significant differences at baseline. The relevant changes at follow-up were: (phase 1) patients in the robot groups showed an improvement in apathy; patients in NAO group showed a decline in cognition as measured by the MMSE scores, but not the sMMSE; the robot groups showed no significant changes between them; (phase 2) QUALID scores increased in the PARO group. In the day care center, 20 patients (phase 1) and 17 patients (phase 2) were included. The main findings were: (phase 1) imp

17 December 2012 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
JOJavier Olazarán
Javier Olazarán
JHJuan Antonio Hernández-Tamames
Juan Antonio Hernández-Tamames
EMElena Molina
Elena Molina
PGPablo García-Polo
Pablo García-Polo
JDJosé Luis Dobato
José Luis Dobato
AIAD Research Unit Investigators
AD Research Unit Investigators
We conducted a cross-sectional study to investigate the clinical and anatomical correlates of gait dysfunction in advanced Alzheimer's disease (AD). A comprehensive clinical protocol that included cognitive, functional, behavioral, and motor variable

1 November 2013 in Archives of Gerontology and Geriatrics
Verified
Journal Article
Closed access
BLBeatriz León-Salas
Beatriz León-Salas
JOJavier Olazarán
Javier Olazarán
ICIsabel Cruz-Orduña
Isabel Cruz-Orduña
LALuis Agüera-Ortiz
Luis Agüera-Ortiz
JDJosé Luis Dobato
José Luis Dobato
PMPablo Martínez-Martín
Pablo Martínez-Martín

18 June 2013 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
JOJavier Olazarán
Javier Olazarán
BGBelén González
Belén González
JLJorge López-Álvarez
Jorge López-Álvarez
ACAlessandro Castagna
Alessandro Castagna
EOEmma Osa-Ruiz
Emma Osa-Ruiz
AIAD Research Unit Investigators
AD Research Unit Investigators
We conducted a pilot, randomized, controlled trial to mainly investigate the feasibility, safety, and short-term motor effects of brain stimulation with radio electric asymmetric conveyer (REAC) technology in patients with advanced Alzheimer's diseas

8 January 2014 in American Journal of Alzheimer's Disease and Other Dementias®
Verified
Journal Article
Closed access
JOJavier Olazarán
Javier Olazarán
ARAna Ramos
Ana Ramos
IBInmaculada Boyano
Inmaculada Boyano
EAEva Alfayate
Eva Alfayate
MVMeritxell Valentí
Meritxell Valentí
JÁJuan Álvarez-Linera
Juan Álvarez-Linera
A cross-sectional study was conducted to describe the prevalence, locations, and risk factors for brain microbleeds (BMBs) in neurodegenerative dementia. The database of the Alzheimer Center Reina Sofía Foundation was searched, BMBs were described, and the potential associations of BMBs were investigated using univariate statistics. A total of 148 patients (age 81.6 [standard deviation 6.7], 79.1% female) were studied. Prevalence of BMBs was 44.6%. A group of patients with unusually high (ie, ≥4) number of BMBs were identified, which displayed higher number of vascular risk factors and vascular diseases. Brain microbleeds were also associated with ischemic lesions in the basal ganglia (r = .39), clinical diagnosis of Alzheimer’s disease (AD) and cerebrovascular disease (r = .33), cortical infarction (r = .20), and antiaggregant or anticoagulant treatment duration (r = .20). Brain microbleeds are associated with vascular burden and AD diagnosis in old patients with neurodegenerative dementia. More research is warranted regarding the mechanisms and potential clinical implications of these results.

12 January 2012 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
JOJavier Olazarán
Javier Olazarán
LALuis Agüera-Ortiz
Luis Agüera-Ortiz
RORicardo S. Osorio
Ricardo S. Osorio
BLBeatriz León-Salas
Beatriz León-Salas
JDJosé Luis Dobato
José Luis Dobato
PMPablo Martínez-Martín
Pablo Martínez-Martín
The Alzheimer Center Reina Sofía Foundation (ACRSF) was envisaged to address the complex and multi-disciplinary research and care needs posed by Alzheimer's disease (AD) and other neurodegenerative dementias. Patients may be admitted at ACRSF either